Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Asset Writedowns and Impairment: 2012-2025

  • BIO-TECHNE's Asset Writedowns and Impairment rose 428.46% to $84.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $115.1 million, marking a year-over-year increase of 123.87%. This contributed to the annual value of $80.5 million for FY2025, which is 266.54% up from last year.
  • As of Q2 2025, BIO-TECHNE's Asset Writedowns and Impairment stood at $84.2 million, which was up 2,402.54% from -$3.7 million recorded in Q1 2025.
  • In the past 5 years, BIO-TECHNE's Asset Writedowns and Impairment registered a high of $84.2 million during Q2 2025, and its lowest value of -$3.7 million during Q1 2025.
  • Over the past 2 years, BIO-TECHNE's median Asset Writedowns and Impairment value was $15.9 million (recorded in 2024), while the average stood at $32.1 million.
  • Data for BIO-TECHNE's Asset Writedowns and Impairment shows a peak YoY soared of 428.46% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows BIO-TECHNE's Asset Writedowns and Impairment stood at $18.7 million in 2021, then reached $15.9 million in 2024, then surged by 428.46% to $84.2 million in 2025.
  • Its last three reported values are $84.2 million in Q2 2025, -$3.7 million for Q1 2025, and $15.9 million during Q2 2024.